Released Mar 19, 2026, after the close
10-K filed Mar 19, 2026, 78 days after period end · 0001193125-26-115992
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$42.47M$42.47M derived+477.3% vs Q4 2024+293.6% vs Q3 2025
Net Income$22.09M$22.09M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$19,799,000N/M
Operating Cash Flowderived$14,237,000N/M
Free Cash Flowderived$14,213,000N/M
Margins · derived
Operating margin46.6%+203.4 pt vs Q4 2024
Net margin52.0%+192.5 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $42.47M | $7.36M | $7.16M | — |
| Net Income | $22.09M | -$10.34M | -$10.96M | -$22.40M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR